Plasma Fractionation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others), By Method (Centrifugation, Depth Filtration, Chromatography, and Others), By Application (Neurology, Hematology, Oncology, Immunology, and Others), By End User (Hospitals & Clinics, Academic &
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationPlasma Fractionation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others), By Method (Centrifugation, Depth Filtration, Chromatography, and Others), By Application (Neurology, Hematology, Oncology, Immunology, and Others), By End User (Hospitals & Clinics, Academic &
According to the Statista, as of 2022, around 51 percent of patients with Bernard Soulier syndrome were female, while to 49 percent were male.
Growing Prevalence of Immunodeficiency disorder
For instance, according to the March 2021 report of the Alzheimer’s Association, approximately 6.2 million people of age 65 years and more are living with Alzheimer’s-related dementia in the United States.
Development of New Technologies
In 2019, there were around 195,263 people worldwide who had been diagnosed with hemophilia and 80,302 who had been diagnosed with von Willebrand disease.
Recent Development
- For instance, in March 2021, according to the WHO Model List of essential medicines includes several plasma-derived medicinal products (PDMPs), identifying them as drugs thought to be the most efficient and secure for addressing the most essential requirements in a health system and provide the best guidelines on increased supply of PDMPs in low & middle-income countries
- For instance, in April 2020, to create a viable plasma-derived medication for treating COVID-19, CSL Behring & Takeda Pharmaceutical Company Ltd. collaborated with Biotest, BPL, LFB, and Octapharma.
- For instance, in April 2019, under a long-term initiative to support people with hemophilia, Grifols International SA, a supplier of plasma-derived therapeutics, provided blood clotting factor medications (100 million international units) for the treatment of hemophilic patients.
- Idelvion by CSL BehringIdelvion is an extended half-life factor IX product for the treatment of hemophilia B that was launched in 2018. It is produced using CSL Behring's plasma fractionation technology and is designed to provide longer-lasting protection against bleeding episodes.
- ALPROLIX and ELOCTATE by SanofiThese are two extended half-life factor VIII products for the treatment of hemophilia A that were launched in 2019. They are produced using Sanofi's proprietary plasma fractionation technology and are designed to provide longer-lasting protection against bleeding episodes.
- CUVITRU by TakedaCUVITRU is a subcutaneous immunoglobulin therapy for the treatment of primary immunodeficiency that was launched in 2018. It is produced using Takeda's plasma fractionation technology and is designed to be administered at home by patients or their caregivers.
- Hizentra by CSL BehringHizentra is a subcutaneous immunoglobulin therapy for the treatment of primary immunodeficiency that was launched in 2019. It is produced using CSL Behring's plasma fractionation technology and is designed to provide convenient and flexible dosing options for patients.
- HyperRAB S/D by GrifolsHyperRAB S/D is a rabies immune globulin therapy that was launched in 2020. It is produced using Grifols' plasma fractionation technology and is designed to provide rapid and effective protection against rabies infection.
Market Segmentation
The global plasma fractionation market can be segmented by product, method, application, end user and by region. Based on product, the market can be segmented into Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others. Based on method, the market can be differentiated into Centrifugation, Depth Filtration, Chromatography, and Others. Based on application, the market can be grouped into Neurology, Hematology, Oncology, Immunology, and Others. Based on end user, the market can be segmented into Hospitals & Clinics, Academic & Research Institutes, Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global plasma fractionation market on account of the growing demand for new therapies for the treatment of chronic diseases in the country.
Market Players
Grifols S.A., Octapharma AG, Intas Pharmaceuticals Ltd, LFB S.A., Takeda Pharmaceutical Company Limited, CSL Limited, Biotest AG, Kedrion S.p.A, Bio Products Laboratory Ltd.’, Bharat Serums and Vaccines Limited are some of the leading players operating in the Global Plasma Fractionation Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | · By Product · By Method · By Application · By End User · By Region |
| Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE; Turkey; Egypt |
| Key companies profiled | Grifols S.A., Octapharma AG, Intas Pharmaceuticals Ltd, LFB S.A., Takeda Pharmaceutical Company Limited, CSL Limited, Biotest AG, Kedrion S.p.A, Bio Products Laboratory Ltd.’, Bharat Serums and Vaccines Limited |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy